{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,6]],"date-time":"2026-10-06T07:39:35Z","timestamp":1791272375514,"version":"4.1.0"},"reference-count":109,"publisher":"Bentham Science Publishers Ltd.","issue":"41","funder":[{"DOI":"10.13039\/501100002428","name":"Austrian Science Fund","doi-asserted-by":"publisher","award":["P 27844"],"award-info":[{"award-number":["P 27844"]}],"id":[{"id":"10.13039\/501100002428","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["eurekaselect.com"],"crossmark-restriction":true},"short-container-title":["CMC"],"published-print":{"date-parts":[[2020,12,8]]},"abstract":"<jats:sec>\n                    <jats:title\/>\n                    <jats:p>A wide variety of radiolabeled peptide analogs for specific targeting of cholecystokinin-\n2 receptors (CCK2R) has been developed in the last decades. Peptide probes based\non the natural ligands Minigastrin (MG) and Cholecystokinin (CCK) have a high potential for\nmolecular imaging and targeted radiotherapy of different human tumors, such as Medullary\nThyroid Carcinoma (MTC) and Small Cell Lung Cancer (SCLC). MG analogs with high persistent\nuptake in CCK2R expressing tumors have been preferably used for the development of\nradiolabeled peptide analogs. The clinical translation of CCK2R targeting has been prevented\ndue to high kidney uptake or low metabolic stability of the different radiopeptides developed.\nGreat efforts in radiopharmaceutical development have been undertaken to overcome these\nlimitations. Various modifications in the linear peptide sequence of MG have been introduced\nmainly with the aim to reduce kidney retention. Furthermore, improved tumor uptake could be\nobtained by in situ stabilization of the radiopeptide against enzymatic degradation through coinjection\nof peptidase inhibitors. Recent developments focusing on the stabilization of the Cterminal\nreceptor binding sequence (Trp-Met-Asp-Phe-NH2) have led to new radiolabeled\nMG analogs with highly improved tumor uptake and tumor-to-kidney ratio. In this review, all\nthe different aspects in the radiopharmaceutical development of CCK2R targeting peptide\nprobes are covered, giving also an overview on the clinical investigations performed so far.\nThe recent development of radiolabeled MG analogs, which are highly stabilized against enzymatic\ndegradation in vivo, promises to have a high impact on the clinical management of\npatients with CCK2R expressing tumors in the near future.<\/jats:p>\n                  <\/jats:sec>","DOI":"10.2174\/0929867327666200625143035","type":"journal-article","created":{"date-parts":[[2020,6,26]],"date-time":"2020-06-26T03:08:45Z","timestamp":1593140925000},"page":"7112-7132","update-policy":"https:\/\/doi.org\/10.2174\/bsp_crossmark_policy","source":"Crossref","is-referenced-by-count":35,"title":["Cholecystokinin-2 Receptor Targeting with Radiolabeled Peptides: Current Status and Future Directions"],"prefix":"10.2174","volume":"27","author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-8499-9434","authenticated-orcid":true,"given":"Maximilian","family":"Klingler","sequence":"first","affiliation":[{"name":"Department of Nuclear Medicine, Medical University of Innsbruck, A-6020 Innsbruck, Austria"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-0119-3102","authenticated-orcid":true,"given":"Anton Amadeus","family":"H\u00f6rmann","sequence":"additional","affiliation":[{"name":"Department of Nuclear Medicine, Medical University of Innsbruck, A-6020 Innsbruck, Austria"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-4944-4705","authenticated-orcid":true,"given":"Elisabeth Von","family":"Guggenberg","sequence":"additional","affiliation":[{"name":"Department of Nuclear Medicine, Medical University of Innsbruck, A-6020 Innsbruck, Austria"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"965","reference":[{"key":"ref=1","doi-asserted-by":"publisher","first-page":"102","DOI":"10.1016\/j.drudis.2009.12.003","volume":"15","author":"van der Meel R.","year":"2010","unstructured":"van der Meel R.; Gallagher W.M.; Oliveira S.; O\u2019Connor A.E.; Schiffelers R.M.; Byrne A.T.; Recent advances in molecular imaging biomarkers in cancer: application of bench to bedside technologies. Drug Discov Today 2010,15(3-4),102-114","journal-title":"Drug Discov Today"},{"key":"ref=2","doi-asserted-by":"publisher","first-page":"345","DOI":"10.3389\/fendo.2018.00345","volume":"9","author":"Moody T.W.","year":"2018","unstructured":"Moody T.W.; Ramos-Alvarez I.; Jensen R.T.; Neuropeptide G protein-coupled receptors as oncotargets.  Front Endocrinol (Lausanne) 2018,9,345","journal-title":"Front Endocrinol (Lausanne)"},{"key":"ref=3","doi-asserted-by":"publisher","first-page":"39","DOI":"10.1089\/cbr.2017.2378","volume":"33","author":"Karpuz M.","year":"2018","unstructured":"Karpuz M.; Silindir-Gunay M.; Ozer A.Y.; Current and future approaches for effective cancer imaging and treatment. Cancer Biother Radiopharm 2018,33(2),39-51","journal-title":"Cancer Biother Radiopharm"},{"key":"ref=4","doi-asserted-by":"publisher","first-page":"781","DOI":"10.1007\/s00259-003-1184-3","volume":"30","author":"Reubi J.C.","year":"2003","unstructured":"Reubi J.C.; Waser B.; Concomitant expression of several peptide receptors in neuroendocrine tumours: molecular basis for in vivo multireceptor tumour targeting. Eur J Nucl Med Mol Imaging 2003,30(5),781-793","journal-title":"Eur J Nucl Med Mol Imaging"},{"key":"ref=5","doi-asserted-by":"publisher","first-page":"1","DOI":"10.3390\/ph10010030","volume":"10","author":"Fani M.","year":"2017","unstructured":"Fani M.; Peitl P.K.; Velikyan I.; Current status of radiopharmaceuticals for the theranostics of neuroendocrine neoplasms. Pharmaceuticals (Basel) 2017,10(1),1-22","journal-title":"Pharmaceuticals (Basel)"},{"key":"ref=6","doi-asserted-by":"publisher","first-page":"1481","DOI":"10.2967\/jnumed.112.102764","volume":"53","author":"Fani M.","year":"2012","unstructured":"Fani M.; Braun F.; Waser B.; Beetschen K.; Cescato R.; Erchegyi J.; Rivier J.E.; Weber W.A.; Maecke H.R.; Reubi J.C.; Unex-pected sensitivity of sst2 antagonists to N-terminal radiometal modifications. J Nucl Med 2012,53(9),1481-1489","journal-title":"J Nucl Med"},{"key":"ref=7","doi-asserted-by":"publisher","first-page":"47","DOI":"10.1089\/cbr.2014.1741","volume":"30","author":"Dash A.","year":"2015","unstructured":"Dash A.; Chakraborty S.; Pillai M.R.A.; Knapp F.F.; Jr. Peptide receptor radionuclide therapy: an overview. Cancer Biother Radiopharm 2015,30(2),47-71","journal-title":"Cancer Biother Radiopharm"},{"key":"ref=8","doi-asserted-by":"publisher","first-page":"167","DOI":"10.2967\/jnumed.118.213496","volume":"60","author":"Nicolas G.P.","year":"2018","unstructured":"Nicolas G.P.; Morgenstern A.; Schottelius M.; Fani M.; New developments in peptide receptor radionuclide therapy. J Nucl Med 2018,60(2),167-171","journal-title":"J Nucl Med"},{"key":"ref=9","doi-asserted-by":"publisher","first-page":"242","DOI":"10.1016\/S0140-6736(89)91258-0","volume":"1","author":"Krenning E.P.","year":"1989","unstructured":"Krenning E.P.; Bakker W.H.; Breeman W.A.; Koper J.W.; Kooij P.P.; Ausema L.; Lameris J.S.; Reubi J.C.; Lamberts S.W.; Localisation of endocrine-related tumours with radioiodinated analogue of somatostatin. Lancet 1989,1(8632),242-244","journal-title":"Lancet"},{"key":"ref=10","doi-asserted-by":"publisher","first-page":"167","DOI":"10.3109\/02841869309083907","volume":"32","author":"Lamberts S.W.J.","year":"1993","unstructured":"Lamberts S.W.J.; Reubi J.C.; Krenning E.P.; Validation of somatostatin receptor scintigraphy in the localization of neuroendocrine tumors. Acta Oncol 1993,32(2),167-170","journal-title":"Acta Oncol"},{"key":"ref=11","doi-asserted-by":"publisher","first-page":"S11","DOI":"10.1007\/s00259-011-2001-z","volume":"39","author":"Fani M.","year":"2012","unstructured":"Fani M.; Maecke H.R.; Radiopharmaceutical development of radiolabelled peptides. Eur J Nucl Med Mol Imaging 2012,39(Suppl. 1),S11-S30","journal-title":"Eur J Nucl Med Mol Imaging"},{"key":"ref=12","doi-asserted-by":"publisher","DOI":"10.1259\/bjr.20180440","volume":"91","author":"Turner J.H.","year":"2018","unstructured":"Turner J.H.; An introduction to the clinical practice of theranostics in oncology. Br J Radiol 2018,91(1091)","journal-title":"Br J Radiol"},{"key":"ref=13","doi-asserted-by":"publisher","first-page":"740","DOI":"10.3109\/00365521.2015.1033454","volume":"50","author":"Kjaer A.","year":"2015","unstructured":"Kjaer A.; Knigge U.; Use of radioactive substances in diagnosis and treatment of neuroendocrine tumors. Scand J Gastroenterol 2015,50(6),740-747","journal-title":"Scand J Gastroenterol"},{"key":"ref=14","doi-asserted-by":"publisher","first-page":"508","DOI":"10.2967\/jnumed.106.035667","volume":"48","author":"Gabriel M.","year":"2007","unstructured":"Gabriel M.; Decristoforo C.; Kendler D.; Dobrozemsky G.; Heute D.; Uprimny C.; Kovacs P.; Von Guggenberg E.; Bale R.; Virgolini I.J.; 68Ga-DOTA-Tyr3-octreotide PET in neuroendocrine tumors: comparison with somatostatin receptor scintigraphy and CT. J Nucl Med 2007,48(4),508-518","journal-title":"J Nucl Med"},{"key":"ref=15","doi-asserted-by":"publisher","first-page":"125","DOI":"10.1056\/NEJMoa1607427","volume":"376","author":"Strosberg J.","year":"2017","unstructured":"Strosberg J.; El-Haddad G.; Wolin E.; Hendifar A.; Yao J.; Chasen B.; Mittra E.; Kunz P.L.; Kulke M.H.; Jacene H.; Bushnell D.; O\u2019Dorisio T.M.; Baum R.P.; Kulkarni H.R.; Caplin M.; Lebtahi R.; Hobday T.; Delpassand E.; Van Cutsem E.; Benson A.; Srirajaskanthan R.; Pavel M.; Mora J.; Berlin J.; Grande E.; Reed N.; Seregni E.; \u00d6berg K.; Lopera Sierra M.; Santoro P.; Thevenet T.; Erion J.L.; Ruszniewski P.; Kwekkeboom D.; Krenning E.; NETTER-1 trial investigators. Phase 3 trial of Lu-DOTAPPtate for midgut neuroendocrine tumors. N Engl J Med 2017,376(2),125-135","journal-title":"N Engl J Med"},{"key":"ref=16","doi-asserted-by":"publisher","first-page":"1239","DOI":"10.2174\/156802607780960546","volume":"7","author":"Reubi J.C.","year":"2007","unstructured":"Reubi J.C.; Targeting CCK receptors in human cancers. Curr Top Med Chem 2007,7(12),1239-1242","journal-title":"Curr Top Med Chem"},{"key":"ref=17","doi-asserted-by":"publisher","first-page":"170","DOI":"10.1016\/j.mce.2011.10.010","volume":"349","author":"Sanchez C.","year":"2012","unstructured":"Sanchez C.; Escrieut C.; Clerc P.; Gigoux V.; Waser B.; Reubi J.C.; Fourmy D.; Characterization of a novel five-transmembrane domain cholecystokinin-2 receptor splice variant identified in human tumors. Mol Cell Endocrinol 2012,349(2),170-179","journal-title":"Mol Cell Endocrinol"},{"key":"ref=18","first-page":"1377","volume":"57","author":"Reubi J.C.","year":"1997","unstructured":"Reubi J.C.; Schaer J.C.; Waser B.; Cholecystokinin (CCK)-A and CCK-B\/gastrin receptors in human tumors. Cancer Res 1997,57(7),1377-1386","journal-title":"Cancer Res"},{"key":"ref=19","doi-asserted-by":"publisher","DOI":"10.1155\/2018\/2149532","volume":"2018","author":"Liu H.","year":"2018","unstructured":"Liu H.; Wang X.; Yang R.; Zeng W.; Peng D.; Li J.; Wang H.; Recent development of nuclear molecular imaging in thyroid cancer. BioMed Res Int 2018,2018","journal-title":"BioMed Res Int"},{"key":"ref=20","doi-asserted-by":"publisher","first-page":"W867","DOI":"10.2214\/AJR.12.10370","volume":"201","author":"Ganeshan D.","year":"2013","unstructured":"Ganeshan D.; Paulson E.; Duran C.; Cabanillas M.E.; Busaidy N.L.; Charnsangavej C.; Current update on medullary thyroid carci-noma. AJR Am J Roentgenol 2013,201(6),W867-W876","journal-title":"AJR Am J Roentgenol"},{"key":"ref=21","doi-asserted-by":"publisher","first-page":"285","DOI":"10.1016\/j.ecl.2018.11.006","volume":"48","author":"Viola D.","year":"2019","unstructured":"Viola D.; Elisei R.; Management of medullary thyroid cancer. Endocrinol Metab Clin North Am 2019,48(1),285-301","journal-title":"Endocrinol Metab Clin North Am"},{"key":"ref=22","doi-asserted-by":"publisher","first-page":"2655","DOI":"10.1210\/jc.2009-2368","volume":"95","author":"Machens A.","year":"2010","unstructured":"Machens A.; Dralle H.; Biomarker-based risk stratification for previously untreated medullary thyroid cancer. J Clin Endocrinol Metab 2010,95(6),2655-2663","journal-title":"J Clin Endocrinol Metab"},{"key":"ref=23","doi-asserted-by":"publisher","first-page":"25","DOI":"10.1097\/CCO.0000000000000340","volume":"29","author":"Maia A.L.","year":"2017","unstructured":"Maia A.L.; Wajner S.M.; Vargas C.V.; Advances and controversies in the management of medullary thyroid carcinoma. Curr Opin Oncol 2017,29(1),25-32","journal-title":"Curr Opin Oncol"},{"key":"ref=24","doi-asserted-by":"publisher","first-page":"569","DOI":"10.1007\/s00259-011-2031-6","volume":"39","author":"Treglia G.","year":"2012","unstructured":"Treglia G.; Castaldi P.; Villani M.F.; Perotti G.; de Waure C.; Filice A.; Ambrosini V.; Cremonini N.; Santimaria M.; Versari A.; Fanti S.; Giordano A.; Rufini V.; Comparison of 18F-DOPA, 18F-FDG and 68Ga-somatostatin analogue PET\/CT in patients with recurrent medullary thyroid carcinoma. Eur J Nucl Med Mol Imaging 2012,39(4),569-580","journal-title":"Eur J Nucl Med Mol Imaging"},{"key":"ref=25","doi-asserted-by":"publisher","first-page":"6707","DOI":"10.1074\/jbc.M110.196048","volume":"286","author":"Magnan R.","year":"2011","unstructured":"Magnan R.; Masri B.; Escrieut C.; Foucaud M.; Cordelier P.; Fourmy D.; Regulation of membrane cholecystokinin-2 receptor by agonists enables classification of partial agonists as biased agonists. J Biol Chem 2011,286(8),6707-6719","journal-title":"J Biol Chem"},{"key":"ref=26","doi-asserted-by":"publisher","first-page":"1154","DOI":"10.2174\/156802607780960483","volume":"7","author":"Rehfeld J.F.","year":"2007","unstructured":"Rehfeld J.F.; Friis-Hansen L.; Goetze J.P.; Hansen T.V.O.; The biology of cholecystokinin and gastrin peptides. Curr Top Med Chem 2007,7(12),1154-1165","journal-title":"Curr Top Med Chem"},{"key":"ref=27","doi-asserted-by":"publisher","first-page":"1189","DOI":"10.1038\/sj.bjp.0701713","volume":"123","author":"Smeets R.L.","year":"1998","unstructured":"Smeets R.L.; Fouraux M.A.; van Emst-de Vries S.E.; De Pont J.J.; Willems P.H.; Protein kinase C-mediated inhibition of trans-membrane signalling through CCK(A) and CCK(B) receptors. Br J Pharmacol 1998,123(6),1189-1197","journal-title":"Br J Pharmacol"},{"key":"ref=28","doi-asserted-by":"publisher","first-page":"805","DOI":"10.1152\/physrev.00014.2005","volume":"86","author":"Dufresne M.","year":"2006","unstructured":"Dufresne M.; Seva C.; Fourmy D.; Cholecystokinin and gastrin receptors. Physiol Rev 2006,86(3),805-847","journal-title":"Physiol Rev"},{"key":"ref=29","first-page":"745","volume":"51","author":"Noble F.","year":"1999","unstructured":"Noble F.; Wank S.A.; Crawley J.N.; Bradwejn J.; Seroogy K.B.; Hamon M.; Roques B.P.; International Union of Pharmacology. XXI. Structure, distribution and functions of cholecystokinin receptors. Pharmacol Rev 1999,51(4),745-781","journal-title":"Pharmacol Rev"},{"key":"ref=30","doi-asserted-by":"publisher","first-page":"481","DOI":"10.7150\/thno.4024","volume":"2","author":"Fani M.","year":"2012","unstructured":"Fani M.; Maecke H.R.; Okarvi S.M.; Radiolabeled peptides: valuable tools for the detection and treatment of cancer. Theranostics 2012,2(5),481-501","journal-title":"Theranostics"},{"key":"ref=31","doi-asserted-by":"publisher","first-page":"1049","DOI":"10.1007\/s00726-010-0501-y","volume":"41","author":"Roosenburg S.","year":"2011","unstructured":"Roosenburg S.; Laverman P.; van Delft F.L.; Boerman O.C.; Radiolabeled CCK\/gastrin peptides for imaging and therapy of CCK2 receptor-expressing tumors. Amino Acids 2011,41(5),1049-1058","journal-title":"Amino Acids"},{"key":"ref=32","first-page":"287","volume":"59","author":"Kaloudi A.","year":"2015","unstructured":"Kaloudi A.; Nock B.A.; Krenning E.P.; Maina T.; De Jong M.; Radiolabeled gastrin\/CCK analogs in tumor diagnosis: towards higher stability and improved tumor targeting. Q J Nucl Med Mol Imaging 2015,59(3),287-302","journal-title":"Q J Nucl Med Mol Imaging"},{"key":"ref=33","doi-asserted-by":"publisher","first-page":"370","DOI":"10.1002\/bip.10347","volume":"66","author":"Aloj L.","year":"2002","unstructured":"Aloj L.; Panico M.R.; Carac\u00f3 C.; Zannetti A.; Del Vecchio S.; Di Nuzzo C.; Arra C.; Morelli G.; Tesauro D.; De Luca S.; Pedone C.; Salvatore M.; Radiolabeling approaches for cholecystokinin B receptor imaging. Biopolymers 2002,66(6),370-380","journal-title":"Biopolymers"},{"key":"ref=34","doi-asserted-by":"publisher","first-page":"424","DOI":"10.1007\/s002590050241","volume":"25","author":"Behr T.M.","year":"1998","unstructured":"Behr T.M.; Jenner N.; Radetzky S.; B\u00e9he M.; Gratz S.; Y\u00fccekent S.; Raue F.; Becker W.; Targeting of cholecystokinin-B\/gastrin receptors in vivo: preclinical and initial clinical evaluation of the diagnostic and therapeutic potential of radiolabelled gastrin. Eur J Nucl Med 1998,25(4),424-430","journal-title":"Eur J Nucl Med"},{"key":"ref=35","first-page":"3124s","volume":"5","author":"Behr T.M.","year":"1999","unstructured":"Behr T.M.; B\u00e9h\u00e9 M.; Angerstein C.; Gratz S.; Mach R.; Hagemann L.; Jenner N.; Stiehler M.; Frank-Raue K.; Raue F.; Becker W.; Cholecystokinin-B\/gastrin receptor binding peptides: preclinical development and evaluation of their diagnostic and therapeutic potential. Clin Cancer Res 1999,5(Suppl. 10),3124s-3138s","journal-title":"Clin Cancer Res"},{"key":"ref=36","doi-asserted-by":"publisher","first-page":"864","DOI":"10.1021\/bc0300807","volume":"15","author":"von Guggenberg E.","year":"2004","unstructured":"von Guggenberg E.; Behe M.; Behr T.M.; Saurer M.; Seppi T.; Decristoforo C.; 99mTc-labeling and in vitro and in vivo evaluation of HYNIC- and (Nalpha-His)acetic acid-modified [D-Glu1]-minigastrin. Bioconjug Chem 2004,15(4),864-871","journal-title":"Bioconjug Chem"},{"key":"ref=37","first-page":"2081","volume":"40","author":"de Jong M.","year":"1999","unstructured":"de Jong M.; Bakker W.H.; Bernard B.F.; Valkema R.; Kwekkeboom D.J.; Reubi J.C.; Srinivasan A.; Schmidt M.; Krenning E.P.; Preclinical and initial clinical evaluation of 111In-labeled nonsulfated CCK8 analog: a peptide for CCK-B receptor-targeted scintigraphy and radionuclide therapy. J Nucl Med 1999,40(12),2081-2087","journal-title":"J Nucl Med"},{"key":"ref=38","doi-asserted-by":"publisher","first-page":"386","DOI":"10.1007\/s00259-007-0604-1","volume":"35","author":"Laverman P.","year":"2008","unstructured":"Laverman P.; Roosenburg S.; Gotthardt M.; Park J.; Oyen W.J.G.; de Jong M.; Hellmich M.R.; Rutjes F.P.J.T.; van Delft F.L.; Boerman O.C.; Targeting of a CCK(2) receptor splice variant with (111)In-labelled cholecystokinin-8 (CCK8) and (111)In-labelled minigastrin. Eur J Nucl Med Mol Imaging 2008,35(2),386-392","journal-title":"Eur J Nucl Med Mol Imaging"},{"key":"ref=39","doi-asserted-by":"publisher","first-page":"561","DOI":"10.1021\/bc034208w","volume":"15","author":"Laverman P.","year":"2004","unstructured":"Laverman P.; B\u00e9h\u00e9 M.; Oyen W.J.G.; Willems P.H.G.M.; Corstens F.H.M.; Behr T.M.; Boerman O.C.; Two technetium-99m-labeled cholecystokinin-8 (CCK8) peptides for scintigraphic imaging of CCK receptors. Bioconjug Chem 2004,15(3),561-568","journal-title":"Bioconjug Chem"},{"key":"ref=40","first-page":"485","volume":"45","author":"Aloj L.","year":"2004","unstructured":"Aloj L.; Carac\u00f2 C.; Panico M.; Zannetti A.; Del Vecchio S.; Tesauro D.; De Luca S.; Arra C.; Pedone C.; Morelli G.; Salvatore M.; In vitro and in vivo evaluation of 111In-DTPAGlu-G-CCK8 for cholecystokinin-B receptor imaging. J Nucl Med 2004,45(3),485-494","journal-title":"J Nucl Med"},{"key":"ref=41","doi-asserted-by":"publisher","first-page":"1417","DOI":"10.1007\/s00259-011-1816-y","volume":"38","author":"Aloj L.","year":"2011","unstructured":"Aloj L.; Aurilio M.; Rinaldi V.; D\u2019ambrosio L.; Tesauro D.; Peitl P.K.; Maina T.; Mansi R.; von Guggenberg E.; Joosten L.; Sosabowski J.K.; Breeman W.A.P.; De Blois E.; Koelewijn S.; Melis M.; Waser B.; Beetschen K.; Reubi J.C.; de Jong M.; Comparison of the binding and internalization properties of 12 DOTA-coupled and In-labelled CCK2\/gastrin receptor binding pep-tides: a collaborative project under COST Action BM0607. Eur J Nucl Med Mol Imaging 2011,38(8),1417-1425","journal-title":"Eur J Nucl Med Mol Imaging"},{"key":"ref=42","doi-asserted-by":"publisher","first-page":"393","DOI":"10.2967\/jnumed.118.207845","volume":"60","author":"Sauter A.W.","year":"2019","unstructured":"Sauter A.W.; Mansi R.; Hassiepen U.; Muller L.; Panigada T.; Wiehr S.; Wild A-M.; Geistlich S.; B\u00e9h\u00e9 M.; Rottenburger C.; Wild D.; Fani M.; Targeting of the cholecystokinin-2 receptor with the minigastrin analog Lu-DOTAPP-PP-F11N: does the use of protease inhibitors further improve in vivo distribution? J Nucl Med 2019,60(3),393-399","journal-title":"J Nucl Med"},{"key":"ref=43","first-page":"1029","volume":"40","author":"Behr T.M.","year":"1999","unstructured":"Behr T.M.; Jenner N.; B\u00e9h\u00e9 M.; Angerstein C.; Gratz S.; Raue F.; Becker W.; Radiolabeled peptides for targeting cholecystokinin-B\/gastrin receptor-expressing tumors. J Nucl Med 1999,40(6),1029-1044","journal-title":"J Nucl Med"},{"key":"ref=44","doi-asserted-by":"publisher","first-page":"1140","DOI":"10.1007\/s00259-003-1178-1","volume":"30","author":"B\u00e9h\u00e9 M.","year":"2003","unstructured":"B\u00e9h\u00e9 M.; Becker W.; Gotthardt M.; Angerstein C.; Behr T.M.; Improved kinetic stability of DTPA- dGlu as compared with con-ventional monofunctional DTPA in chelating indium and yttrium: preclinical and initial clinical evaluation of radiometal labelled minigastrin derivatives. Eur J Nucl Med Mol Imaging 2003,30(8),1140-1146","journal-title":"Eur J Nucl Med Mol Imaging"},{"key":"ref=45","first-page":"1012","volume":"46","author":"B\u00e9h\u00e9 M.","year":"2005","unstructured":"B\u00e9h\u00e9 M.; Kluge G.; Becker W.; Gotthardt M.; Behr T.M.; Use of polyglutamic acids to reduce uptake of radiometal-labeled minigastrin in the kidneys. J Nucl Med 2005,46(6),1012-1015","journal-title":"J Nucl Med"},{"key":"ref=46","doi-asserted-by":"publisher","first-page":"596","DOI":"10.2967\/jnumed.106.036020","volume":"48","author":"Gotthardt M.","year":"2007","unstructured":"Gotthardt M.; van Eerd-Vismale J.; Oyen W.J.; de Jong M.; Zhang H.; Rolleman E.; Maecke H.R.; B\u00e9h\u00e9 M.; Boerman O.; Indi-cation for different mechanisms of kidney uptake of radiolabeled peptides. J Nucl Med 2007,48(4),596-601","journal-title":"J Nucl Med"},{"key":"ref=47","doi-asserted-by":"publisher","first-page":"1868","DOI":"10.1007\/s00259-008-0803-4","volume":"35","author":"Good S.","year":"2008","unstructured":"Good S.; Walter M.A.; Waser B.; Wang X.; M\u00fcller-Brand J.; B\u00e9h\u00e9 M.P.; Reubi J.C.; Maecke H.R.; Macrocyclic chelator-coupled gastrin-based radiopharmaceuticals for targeting of gastrin receptor-expressing tumours. Eur J Nucl Med Mol Imaging 2008,35(10),1868-1877","journal-title":"Eur J Nucl Med Mol Imaging"},{"key":"ref=48","doi-asserted-by":"publisher","first-page":"93","DOI":"10.1089\/108497804773391739","volume":"19","author":"Aloj L.","year":"2004","unstructured":"Aloj L.; Panico M.; Caraco C.; Del Vecchio S.; Arra C.; Affuso A.; Accardo A.; Mansi R.; Tesauro D.; De Luca S.; Pedone C.; Visentin R.; Mazzi U.; Morelli G.; Salvatore M.; In vitro and in vivo characterization of Indium-111 and Technetium-99m labeled CCK-8 derivatives for CCK-B receptor imaging. Cancer Biother Radiopharm 2004,19(1),93-98","journal-title":"Cancer Biother Radiopharm"},{"key":"ref=49","doi-asserted-by":"publisher","first-page":"1209","DOI":"10.1007\/s00259-006-0348-3","volume":"34","author":"von Guggenberg E.","year":"2007","unstructured":"von Guggenberg E.; Dietrich H.; Skvortsova I.; Gabriel M.; Virgolini I.J.; Decristoforo C.; 99mTc-labelled HYNIC-minigastrin with reduced kidney uptake for targeting of CCK-2 receptor-positive tumours. Eur J Nucl Med Mol Imaging 2007,34(8),1209-1218","journal-title":"Eur J Nucl Med Mol Imaging"},{"key":"ref=50","doi-asserted-by":"publisher","first-page":"707","DOI":"10.1002\/bip.21041","volume":"90","author":"D\u2019Andrea L.D.","year":"2008","unstructured":"D\u2019Andrea L.D.; Testa I.; Panico M.; Di Stasi R.; Carac\u00f2 C.; Tarallo L.; Arra C.; Barbieri A.; Romanelli A.; Aloj L.; In vivo and in vitro characterization of CCK8 bearing a histidine-based chelator labeled with 99mTc-tricarbonyl. Biopolymers 2008,90(5),707-712","journal-title":"Biopolymers"},{"key":"ref=51","doi-asserted-by":"publisher","first-page":"347","DOI":"10.1016\/j.nucmedbio.2016.03.003","volume":"43","author":"Kaloudi A.","year":"2016","unstructured":"Kaloudi A.; Nock B.A.; Lymperis E.; Krenning E.P.; de Jong M.; Maina T.; (99m)Tc-labeled gastrins of varying peptide chain length: Distinct impact of NEP\/ACE-inhibition on stability and tumor uptake in mice. Nucl Med Biol 2016,43(6),347-354","journal-title":"Nucl Med Biol"},{"key":"ref=52","first-page":"1727","volume":"46","author":"Nock B.A.","year":"2005","unstructured":"Nock B.A.; Maina T.; B\u00e9h\u00e9 M.; Nikolopoulou A.; Gotthardt M.; Schmitt J.S.; Behr T.M.; M\u00e4cke H.R.; CCK-2\/gastrin receptor-targeted tumor imaging with (99m)Tc-labeled minigastrin analogs. J Nucl Med 2005,46(10),1727-1736","journal-title":"J Nucl Med"},{"key":"ref=53","doi-asserted-by":"publisher","first-page":"2082","DOI":"10.2967\/jnumed.109.064808","volume":"50","author":"Sosabowski J.K.","year":"2009","unstructured":"Sosabowski J.K.; Matzow T.; Foster J.M.; Finucane C.; Ellison D.; Watson S.A.; Mather S.J.; Targeting of CCK-2 receptor-expressing tumors using a radiolabeled divalent gastrin peptide. J Nucl Med 2009,50(12),2082-2089","journal-title":"J Nucl Med"},{"key":"ref=54","doi-asserted-by":"publisher","DOI":"10.1371\/journal.pone.0201224","volume":"13","author":"Summer D.","year":"2018","unstructured":"Summer D.; Kroess A.; Woerndle R.; Rangger C.; Klingler M.; Haas H.; Kremser L.; Lindner H.H.; von Guggenberg E.; De-cristoforo C.; Multimerization results in formation of re-bindable metabolites: a proof of concept study with FSC-based minigastrin imaging probes targeting CCK2R expression. PLoS One 2018,13(7)","journal-title":"PLoS One"},{"key":"ref=55","doi-asserted-by":"publisher","DOI":"10.1155\/2018\/3171794","volume":"2018","author":"Summer D.","year":"2018","unstructured":"Summer D.; Rangger C.; Klingler M.; Laverman P.; Franssen G.M.; Lechner B.E.; Orasch T.; Haas H.; von Guggenberg E.; Decristoforo C.; Exploiting the concept of multivalency with 68Ga- and 89Zr-labelled fusarinine C-minigastrin bioconjugates for targeting CCK2R expression. Contrast Media Mol Imaging 2018,2018","journal-title":"Contrast Media Mol Imaging"},{"key":"ref=56","doi-asserted-by":"publisher","first-page":"4786","DOI":"10.1021\/jm900400w","volume":"52","author":"von Guggenberg E.","year":"2009","unstructured":"von Guggenberg E.; Sallegger W.; Helbok A.; Ocak M.; King R.; Mather S.J.; Decristoforo C.; Cyclic minigastrin analogues for gastrin receptor scintigraphy with technetium-99m: preclinical evaluation. J Med Chem 2009,52(15),4786-4793","journal-title":"J Med Chem"},{"key":"ref=57","doi-asserted-by":"publisher","first-page":"366","DOI":"10.1007\/s11307-011-0506-2","volume":"14","author":"von Guggenberg E.","year":"2012","unstructured":"von Guggenberg E.; Rangger C.; Sosabowski J.; Laverman P.; Reubi J.C.; Virgolini I.J.; Decristoforo C.; Preclinical evaluation of radiolabeled DOTA-derivatized cyclic minigastrin analogs for targeting cholecystokinin receptor expressing malignancies. Mol Imaging Biol 2012,14(3),366-375","journal-title":"Mol Imaging Biol"},{"key":"ref=58","doi-asserted-by":"publisher","first-page":"2602","DOI":"10.1021\/jm101279a","volume":"54","author":"Kolenc-Peitl P.","year":"2011","unstructured":"Kolenc-Peitl P.; Mansi R.; Tamma M.; Gmeiner-Stopar T.; Sollner-Dolenc M.; Waser B.; Baum R.P.; Reubi J.C.; Maecke H.R.; Highly improved metabolic stability and pharmacokinetics of indium-111-DOTA-gastrin conjugates for targeting of the gastrin receptor. J Med Chem 2011,54(8),2602-2609","journal-title":"J Med Chem"},{"key":"ref=59","doi-asserted-by":"publisher","first-page":"1426","DOI":"10.1007\/s00259-011-1818-9","volume":"38","author":"Ocak M.","year":"2011","unstructured":"Ocak M.; Helbok A.; Rangger C.; Peitl P.K.; Nock B.A.; Morelli G.; Eek A.; Sosabowski J.K.; Breeman W.A.P.; Reubi J.C.; Decristoforo C.; Comparison of biological stability and metabolism of CCK2 receptor targeting peptides, a collaborative project under COST BM0607. Eur J Nucl Med Mol Imaging 2011,38(8),1426-1435","journal-title":"Eur J Nucl Med Mol Imaging"},{"key":"ref=60","doi-asserted-by":"publisher","first-page":"1410","DOI":"10.1007\/s00259-011-1806-0","volume":"38","author":"Laverman P.","year":"2011","unstructured":"Laverman P.; Joosten L.; Eek A.; Roosenburg S.; Peitl P.K.; Maina T.; M\u00e4cke H.; Aloj L.; von Guggenberg E.; Sosabowski J.K.; de Jong M.; Reubi J.C.; Oyen W.J.G.; Boerman O.C.; Comparative biodistribution of 12 In-labelled gastrin\/CCK2 receptor-targeting peptides. Eur J Nucl Med Mol Imaging 2011,38(8),1410-1416","journal-title":"Eur J Nucl Med Mol Imaging"},{"key":"ref=61","doi-asserted-by":"publisher","first-page":"615","DOI":"10.2967\/jnumed.106.037085","volume":"48","author":"Mather S.J.","year":"2007","unstructured":"Mather S.J.; McKenzie A.J.; Sosabowski J.K.; Morris T.M.; Ellison D.; Watson S.A.; Selection of radiolabeled gastrin analogs for peptide receptor-targeted radionuclide therapy. J Nucl Med 2007,48(4),615-622","journal-title":"J Nucl Med"},{"key":"ref=62","doi-asserted-by":"publisher","first-page":"663","DOI":"10.1021\/bc900465y","volume":"21","author":"Roosenburg S.","year":"2010","unstructured":"Roosenburg S.; Laverman P.; Joosten L.; Eek A.; Oyen W.J.G.; de Jong M.; Rutjes F.P.J.T.; van Delft F.L.; Boerman O.C.; Sta-bilized (111)in-labeled sCCK8 analogues for targeting CCK2-receptor positive tumors: synthesis and evaluation. Bioconjug Chem 2010,21(4),663-670","journal-title":"Bioconjug Chem"},{"key":"ref=63","doi-asserted-by":"publisher","first-page":"401","DOI":"10.2310\/7290.2012.00001","volume":"11","author":"Roosenburg S.","year":"2012","unstructured":"Roosenburg S.; Laverman P.; Joosten L.; Eek A.; Rutjes F.P.J.T.; van Delft F.L.; Boerman O.C.; In vitro and in vivo characterization of three 68Ga- and 111In-labeled peptides for cholecystokinin receptor imaging. Mol Imaging 2012,11(5),401-407","journal-title":"Mol Imaging"},{"key":"ref=64","doi-asserted-by":"publisher","first-page":"38","DOI":"10.1002\/psc.2948","volume":"23","author":"Grob N.M.","year":"2017","unstructured":"Grob N.M.; Behe M.; von Guggenberg E.; Schibli R.; Mindt T.L.; Methoxinine - an alternative stable amino acid substitute for oxidation-sensitive methionine in radiolabelled peptide conjugates. J Pept Sci 2017,23(1),38-44","journal-title":"J Pept Sci"},{"key":"ref=65","doi-asserted-by":"publisher","first-page":"304","DOI":"10.2174\/1874471010902040304","volume":"2","author":"Helbok A.","year":"2009","unstructured":"Helbok A.; Decristoforo C.; Behe M.; Rangger C.; Guggenberg E.; Preclinical evaluation of In-111 and Ga-68 labelled minigastrin analogues for CCK-2 receptor imaging. Curr Radiopharm 2009,2(4),304-310","journal-title":"Curr Radiopharm"},{"key":"ref=66","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1016\/j.ejps.2016.01.023","volume":"85","author":"Pawlak D.","year":"2016","unstructured":"Pawlak D.; Rangger C.; Kolenc Peitl P.; Garnuszek P.; Maurin M.; Ihli L.; Kroselj M.; Maina T.; Maecke H.; Erba P.; Kremser L.; Hubalewska-Dydejczyk A.; Miko\u0142ajczak R.; Decristoforo C.; From preclinical development to clinical application: kit formulation for radiolabelling the minigastrin analogue CP04 with In-111 for a first-in-human clinical trial. Eur J Pharm Sci 2016,85,1-9","journal-title":"Eur J Pharm Sci"},{"key":"ref=67","doi-asserted-by":"publisher","first-page":"236","DOI":"10.1016\/j.ejps.2016.05.011","volume":"91","author":"Maina T.","year":"2016","unstructured":"Maina T.; Konijnenberg M.W.; KolencPeitl, P.; Garnuszek, P.; Nock, B.A.; Kaloudi, A.; Kroselj, M.; Zaletel, K.; Maecke, H.; Mansi, R.; Erba, P.; von Guggenberg, E.; Hubalewska-Dydejczyk, A.; Mikolajczak, R.; Decristoforo, C. Preclinical pharmacokinetics, bi-odistribution, radiation dosimetry and toxicity studies required for regulatory approval of a phase I clinical trial with (111)In-CP04 in medullary thyroid carcinoma patients. Eur J Pharm Sci 2016,91,236-242","journal-title":"Eur J Pharm Sci"},{"key":"ref=68","doi-asserted-by":"publisher","first-page":"1113","DOI":"10.1021\/acs.bioconjchem.5b00187","volume":"26","author":"Kolenc Peitl P.","year":"2015","unstructured":"Kolenc Peitl P.; Tamma M.; Kroselj M.; Braun F.; Waser B.; Reubi J.C.; Sollner Dolenc M.; Maecke H.R.; Mansi R.; Stereo-chemistry of amino acid spacers determines the pharmacokinetics of (111)In-DOTA-minigastrin analogues for targeting the CCK2\/gastrin receptor. Bioconjug Chem 2015,26(6),1113-1119","journal-title":"Bioconjug Chem"},{"key":"ref=69","doi-asserted-by":"publisher","first-page":"47","DOI":"10.1186\/s13550-014-0047-1","volume":"4","author":"Konijnenberg M.W.","year":"2014","unstructured":"Konijnenberg M.W.; Breeman W.A.P.; de Blois E.; Chan H.S.; Boerman O.C.; Laverman P.; Kolenc-Peitl P.; Melis M.; de Jong M.; Therapeutic application of CCK2R-targeting PP-F11: influence of particle range, activity and peptide amount. EJNMMI Res 2014,4(1),47","journal-title":"EJNMMI Res"},{"key":"ref=70","doi-asserted-by":"publisher","first-page":"3045","DOI":"10.1021\/acs.molpharmaceut.7b00241","volume":"14","author":"Rangger C.","year":"2017","unstructured":"Rangger C.; Klingler M.; Balogh L.; P\u00f6st\u00e9nyi Z.; Polyak A.; Pawlak D.; Miko\u0142ajczak R.; von Guggenberg E.; 177Lu labeled cyclic minigastrin analogues with therapeutic activity in CCK2R expressing tumors: preclinical evaluation of a kit formulation. Mol Pharm 2017,14(9),3045-3058","journal-title":"Mol Pharm"},{"key":"ref=71","doi-asserted-by":"publisher","first-page":"973","DOI":"10.2967\/jnumed.109.074310","volume":"51","author":"Melis M.","year":"2010","unstructured":"Melis M.; Vegt E.; Konijnenberg M.W.; de Visser M.; Bijster M.; Vermeij M.; Krenning E.P.; Boerman O.C.; de Jong M.; Ne-phrotoxicity in mice after repeated imaging using 111In-labeled peptides. J Nucl Med 2010,51(6),973-977","journal-title":"J Nucl Med"},{"key":"ref=72","doi-asserted-by":"publisher","first-page":"3930","DOI":"10.1021\/mp500283k","volume":"11","author":"Roosenburg S.","year":"2014","unstructured":"Roosenburg S.; Laverman P.; Joosten L.; Cooper M.S.; Kolenc-Peitl P.K.; Foster J.M.; Hudson C.; Leyton J.; Burnet J.; Oyen W.J.G.; Blower P.J.; Mather S.J.; Boerman O.C.; Sosabowski J.K.; PET and SPECT imaging of a radiolabeled minigastrin analogue conjugated with DOTA, NOTA, and NODAGA and labeled with (64)Cu, (68)Ga, and (111). Mol Pharm 2014,11(11),3930-3937","journal-title":"Mol Pharm"},{"key":"ref=73","doi-asserted-by":"publisher","first-page":"51","DOI":"10.5603\/NMR.2015.0014","volume":"18","author":"Maurin M.","year":"2015","unstructured":"Maurin M.; Garnuszek P.; Baran P.; Pawlak D.; Miko\u0142ajczak R.; The radiometal makes a difference. Synthesis and preliminary characterisation of DOTA-minigastrin analogue complexes with Ga, Lu and Y. Nucl Med Rev Cent East Eur 2015,18(2),51-55","journal-title":"Nucl Med Rev Cent East Eur"},{"key":"ref=74","doi-asserted-by":"publisher","first-page":"839","DOI":"10.1016\/j.nucmedbio.2008.09.006","volume":"35","author":"Breeman W.A.P.","year":"2008","unstructured":"Breeman W.A.P.; Fr\u00f6berg A.C.; de Blois E.; van Gameren A.; Melis M.; de Jong M.; Maina T.; Nock B.A.; Erion J.L.; M\u00e4cke H.R.; Krenning E.P.; Optimised labeling, preclinical and initial clinical aspects of CCK-2 receptor-targeting with 3 radiolabeled peptides. Nucl Med Biol 2008,35(8),839-849","journal-title":"Nucl Med Biol"},{"key":"ref=75","first-page":"268","volume":"43","author":"Behr T.M.","year":"1999","unstructured":"Behr T.M.; B\u00e9h\u00e9 M.; Becker W.; Diagnostic applications of radiolabeled peptides in nuclear endocrinology. Q J Nucl Med 1999,43(3),268-280","journal-title":"Q J Nucl Med"},{"key":"ref=76","doi-asserted-by":"publisher","first-page":"1312","DOI":"10.1007\/s002590000296","volume":"27","author":"Kwekkeboom D.J.","year":"2000","unstructured":"Kwekkeboom D.J.; Bakker W.H.; Kooij P.P.M.; Erion J.; Srinivasan A.; de Jong M.; Reubi J.C.; Krenning E.P.; Cholecystokinin receptor imaging using an octapeptide DTPA-CCK analogue in patients with medullary thyroid carcinoma. Eur J Nucl Med 2000,27(9),1312-1317","journal-title":"Eur J Nucl Med"},{"key":"ref=77","doi-asserted-by":"publisher","first-page":"399","DOI":"10.1002\/bip.10356","volume":"66","author":"B\u00e9h\u00e9 M.","year":"2002","unstructured":"B\u00e9h\u00e9 M.; Behr T.M.; Cholecystokinin-B (CCK-B)\/gastrin receptor targeting peptides for staging and therapy of medullary thyroid cancer and other CCK-B receptor expressing malignancies. Biopolymers 2002,66(6),399-418","journal-title":"Biopolymers"},{"key":"ref=78","doi-asserted-by":"publisher","first-page":"97","DOI":"10.1053\/snuc.2002.31028","volume":"32","author":"Behr T.M.","year":"2002","unstructured":"Behr T.M.; B\u00e9h\u00e9 M.P.; Cholecystokinin-B\/Gastrin receptor-targeting peptides for staging and therapy of medullary thyroid cancer and other cholecystokinin-B receptor-expressing malignancies. Semin Nucl Med 2002,32(2),97-109","journal-title":"Semin Nucl Med"},{"key":"ref=79","doi-asserted-by":"publisher","first-page":"1273","DOI":"10.1007\/s00259-006-0157-8","volume":"33","author":"Gotthardt M.","year":"2006","unstructured":"Gotthardt M.; B\u00e9h\u00e9 M.P.; Beuter D.; Battmann A.; Bauhofer A.; Schurrat T.; Schipper M.; Pollum H.; Oyen W.J.G.; Behr T.M.; Improved tumour detection by gastrin receptor scintigraphy in patients with metastasised medullary thyroid carcinoma. Eur J Nucl Med Mol Imaging 2006,33(11),1273-1279","journal-title":"Eur J Nucl Med Mol Imaging"},{"key":"ref=80","doi-asserted-by":"publisher","first-page":"1203","DOI":"10.1677\/erc.1.01245","volume":"13","author":"Gotthardt M.","year":"2006","unstructured":"Gotthardt M.; B\u00e9h\u00e9 M.P.; Grass J.; Bauhofer A.; Rinke A.; Schipper M.L.; Kalinowski M.; Arnold R.; Oyen W.J.G.; Behr T.M.; Added value of gastrin receptor scintigraphy in comparison to somatostatin receptor scintigraphy in patients with carcinoids and other neuroendocrine tumours. Endocr Relat Cancer 2006,13(4),1203-1211","journal-title":"Endocr Relat Cancer"},{"key":"ref=81","doi-asserted-by":"crossref","first-page":"1023","DOI":"10.1007\/s002590100569","volume":"28","author":"Behr T.","year":"2001","unstructured":"Behr T.; Behe M.; Gotthardt M.; Angerstein C.; Heufelder C.; Becker W.; Cholecystokinin(CCK(-B)\/Gastrin-Receptor bining peptides for diagnosis and therapy of metastatic medullary thyroid cancer. Eur J Nucl Med 2001,28(8),1023","journal-title":"Eur J Nucl Med"},{"key":"ref=82","doi-asserted-by":"publisher","first-page":"1265","DOI":"10.1007\/s00259-009-1098-9","volume":"36","author":"Fr\u00f6berg A.C.","year":"2009","unstructured":"Fr\u00f6berg A.C.; de Jong M.; Nock B.A.; Breeman W.A.P.; Erion J.L.; Maina T.; Verdijsseldonck M.; de Herder W.W.; van der Lugt A.; Kooij P.P.M.; Krenning E.P.; Comparison of three radiolabelled peptide analogues for CCK-2 receptor scintigraphy in me-dullary thyroid carcinoma. Eur J Nucl Med Mol Imaging 2009,36(8),1265-1272","journal-title":"Eur J Nucl Med Mol Imaging"},{"key":"ref=83","first-page":"427","volume":"57","author":"Kosowicz J.","year":"2006","unstructured":"Kosowicz J.; Czepczy\u0144ski R.; Ziemnicka K.; Gryczy\u0144ska M.; Sowi\u0144ski J.; The use of a new analogue DGlu-Octagastrin in scintig-raphy of medullary thyroid carcinoma Endokrynol Pol 2006,57(4),427-430","journal-title":"Endokrynol Pol"},{"key":"ref=84","doi-asserted-by":"publisher","first-page":"613","DOI":"10.1089\/cbr.2006.368","volume":"22","author":"Kosowicz J.","year":"2007","unstructured":"Kosowicz J.; Miko\u0142ajczak R.; Czepczy\u0144ski R.; Ziemnicka K.; Gryczy\u0144ska M.; Sowi\u0144ski J.; Two peptide receptor ligands (99m)Tc-EDDA\/HYNIC-Tyr(3)-octreotide and (99m)Tc-EDDA\/HYNIC-(D)Glu-octagastrin for scintigraphy of medullary thyroid carcinoma. Cancer Biother Radiopharm 2007,22(5),613-628","journal-title":"Cancer Biother Radiopharm"},{"key":"ref=85","doi-asserted-by":"publisher","first-page":"68","DOI":"10.5603\/EP.2016.0010","volume":"67","author":"Kunikowska J.","year":"2016","unstructured":"Kunikowska J.; Ziemnicka K.; Pawlak D.; Rucha\u0142a M.; Kolasa A.; Janicka-Jedy\u0144ska M.; Wo\u017aniak A.; Miko\u0142ajczak R.; Kr\u00f3licki L.; Medullary thyroid carcinoma - PET\/CT imaging with 68Ga-labelled gastrin and somatostatin analogues. Endokrynol Pol 2016,67(1),68-71","journal-title":"Endokrynol Pol"},{"key":"ref=86","first-page":"S339","volume":"46","author":"Hubalewska-Dydejczyk A.","year":"2019","unstructured":"Hubalewska-Dydejczyk A.; Mikolajczak R.; Decristoforo C.; Kolenc-Peitl P.; Erba P.A.; Zaletel K.; Maecke H.; Maina T.; Konijnenberg M.; Garnuszek P.; Trofimiuk-M\u00fcldner M.; Przybylik-Mazurek E.; Virgolini I.; de Jong M.; Froberg A.C.; Rangger C.; Goebel G.; Scarpa L.; Glowa B.; Sk\u00f3rkiewicz K.; Lezaic L.; Solnica B.; Fedak D.; Gaw\u0119da P.; Sowa-Staszczak A.; Nock B.A.; Bergant D.; Rep S.; Lenda-Tracz V.; Phase I.; Clinical trial using a novel CCK2 receptor-localizing radiolabelled peptide probe for personalized diagnosis and therapy of patients with progressive or metastatic medullary thyroid carcinoma - final results. Eur J Nucl Med Mol Imaging 2019,46(Suppl. 1),S339","journal-title":"Eur J Nucl Med Mol Imaging"},{"key":"ref=87","doi-asserted-by":"publisher","DOI":"10.2967\/jnumed.119.233031","author":"Rottenburger C.","year":"2019","unstructured":"Rottenburger C.; Nicolas G.P.; McDougall L.; Kaul F.; Cachovan M.; Vija A.H.; Schibli R.; Geistlich S.; Schumann A.; Rau T.; Glatz K.; Behe M.; Christ E.R.; Wild D.; Cholecystokinin-2 receptor agonist 177Lu-PP-F11N for radionuclide therapy of medullary thyroid carcinoma - results of the lumed phase 0a study. J Nucl Med 2019","journal-title":"J Nucl Med"},{"key":"ref=88","doi-asserted-by":"publisher","first-page":"791","DOI":"10.20452\/pamw.4387","volume":"128","author":"Erba P.A.","year":"2018","unstructured":"Erba P.A.; Maecke H.; Mikolajczak R.; Decristoforo C.; Zaletel K.; Maina-Nock T.; Peitl P.K.; Garnuszek P.; Froberg A.; Goebel G.; de Jong M.; Jabrocka-Hybel A.; Konijnenberg M.; Virgolini I.; Nock B.; Lenda-Tracz W.; Pawlak D.; Rangger C.; Trofimiuk-M\u00fcldner M.; Sowa-Staszczak A.; Tomaszuk M.; von Guggenberg E.; Scarpa L.; Hubalewska-Dydejczyk A.; A novel CCK2\/gastrin receptor-localizing radiolabeled peptide probe for personalized diagnosis and therapy of patients with progressive or metastatic medullary thyroid carcinoma: a multicenter phase I GRAN-T-MTC study. Polish Arch Intern Med 2018,128(12),791-795","journal-title":"Polish Arch Intern Med"},{"key":"ref=89","doi-asserted-by":"publisher","first-page":"1588","DOI":"10.1007\/s00259-017-3728-y","volume":"44","author":"Bozkurt M.F.","year":"2017","unstructured":"Bozkurt M.F.; Virgolini I.; Balogova S.; Beheshti M.; Rubello D.; Decristoforo C.; Ambrosini V.; Kjaer A.; Delgado-Bolton R.; Kunikowska J.; Oyen W.J.G.; Chiti A.; Giammarile F.; Sundin A.; Fanti S.; Guideline for PET\/CT imaging of neuroendocrine ne-oplasms with 68Ga-DOTA-conjugated somatostatin receptor targeting peptides and 18F-DOPA. Eur J Nucl Med Mol Imaging 2017,44(9),1588-1601","journal-title":"Eur J Nucl Med Mol Imaging"},{"key":"ref=90","doi-asserted-by":"publisher","first-page":"1248","DOI":"10.2967\/jnumed.114.138834","volume":"55","author":"Wild D.","year":"2014","unstructured":"Wild D.; Fani M.; Fischer R.; Del Pozzo L.; Kaul F.; Krebs S.; Fischer R.; Rivier J.E.F.; Reubi J.C.; Maecke H.R.; Weber W.A.; Comparison of somatostatin receptor agonist and antagonist for peptide receptor radionuclide therapy: a pilot study. J Nucl Med 2014,55(8),1248-1252","journal-title":"J Nucl Med"},{"key":"ref=91","doi-asserted-by":"publisher","first-page":"389","DOI":"10.1210\/er.2002-0007","volume":"24","author":"Reubi J.C.","year":"2003","unstructured":"Reubi J.C.; Peptide receptors as molecular targets for cancer diagnosis and therapy. Endocr Rev 2003,24(4),389-427","journal-title":"Endocr Rev"},{"key":"ref=92","first-page":"311","volume":"8","author":"Pauwels E.","year":"2018","unstructured":"Pauwels E.; Cleeren F.; Bormans G.; Deroose C.M.; Somatostatin receptor PET ligands - the next generation for clinical practice. Am J Nucl Med Mol Imaging 2018,8(5),311-331","journal-title":"Am J Nucl Med Mol Imaging"},{"key":"ref=93","doi-asserted-by":"publisher","first-page":"55","DOI":"10.1007\/s40336-014-0054-2","volume":"2","author":"Bison S.M.","year":"2014","unstructured":"Bison S.M.; Konijnenberg M.W.; Melis M.; Pool S.E.; Bernsen M.R.; Teunissen J.J.M.; Kwekkeboom D.J.; de Jong M.; Peptide receptor radionuclide therapy using radiolabeled somatostatin analogs: focus on future developments. Clin Transl Imaging 2014,2(1),55-66","journal-title":"Clin Transl Imaging"},{"key":"ref=94","doi-asserted-by":"publisher","first-page":"61S","DOI":"10.2967\/jnumed.116.186783","volume":"58","author":"Fani M.","year":"2017","unstructured":"Fani M.; Nicolas G.P.; Wild D.; Somatostatin receptor antagonists for imaging and therapy. J Nucl Med 2017,58(Suppl. 2),61S-66S","journal-title":"J Nucl Med"},{"key":"ref=95","doi-asserted-by":"publisher","first-page":"2138","DOI":"10.1021\/jm801439x","volume":"52","author":"Akg\u00fcn E.","year":"2009","unstructured":"Akg\u00fcn E.; K\u00f6rner M.; Gao F.; Harikumar K.G.; Waser B.; Reubi J.C.; Portoghese P.S.; Miller L.J.; Synthesis and in vitro charac-terization of radioiodinatable benzodiazepines selective for type 1 and type 2 cholecystokinin receptors. J Med Chem 2009,52(7),2138-2147","journal-title":"J Med Chem"},{"key":"ref=96","doi-asserted-by":"publisher","first-page":"113","DOI":"10.2967\/jnumed.114.144998","volume":"56","author":"Wayua C.","year":"2015","unstructured":"Wayua C.; Low P.S.; Evaluation of a nonpeptidic ligand for imaging of cholecystokinin 2 receptor-expressing cancers. J Nucl Med 2015,56(1),113-119","journal-title":"J Nucl Med"},{"key":"ref=97","doi-asserted-by":"publisher","first-page":"121","DOI":"10.2967\/jnumed.113.129411","volume":"55","author":"Nock B.A.","year":"2014","unstructured":"Nock B.A.; Maina T.; Krenning E.P.; de Jong M.; \u201cTo serve and protect\u201d: enzyme inhibitors as radiopeptide escorts promote tumor targeting. J Nucl Med 2014,55(1),121-127","journal-title":"J Nucl Med"},{"key":"ref=98","doi-asserted-by":"publisher","first-page":"125","DOI":"10.1042\/bj2620125","volume":"262","author":"Dubreuil P.","year":"1989","unstructured":"Dubreuil P.; Fulcrand P.; Rodriguez M.; Fulcrand H.; Laur J.; Martinez J.; Novel activity of angiotensin-converting enzyme. Hy-drolysis of cholecystokinin and gastrin analogues with release of the amidated C-terminal dipeptide. Biochem J 1989,262(1),125-130","journal-title":"Biochem J"},{"key":"ref=99","doi-asserted-by":"publisher","first-page":"601","DOI":"10.1016\/0196-9781(96)00036-8","volume":"17","author":"Migaud M.","year":"1996","unstructured":"Migaud M.; Durieux C.; Viereck J.; Soroca-Lucas E.; Fourni\u00e9-Zaluski M.C.; Roques B.P.; The in vivo metabolism of cholecysto-kinin (CCK-8) is essentially ensured by aminopeptidase A. Peptides 1996,17(4),601-607","journal-title":"Peptides"},{"key":"ref=100","doi-asserted-by":"publisher","first-page":"20","DOI":"10.1089\/cbr.2015.1935","volume":"31","author":"Kaloudi A.","year":"2016","unstructured":"Kaloudi A.; Nock B.A.; Lymperis E.; Krenning E.P.; de Jong M.; Maina T.; Improving the in vivo profile of minigastrin radiotracers: a comparative study involving the neutral endopeptidase inhibitor phosphoramidon. Cancer Biother Radiopharm 2016,31(1),20-28","journal-title":"Cancer Biother Radiopharm"},{"key":"ref=101","doi-asserted-by":"publisher","first-page":"15","DOI":"10.1186\/s13550-015-0158-3","volume":"6","author":"Kaloudi A.","year":"2016","unstructured":"Kaloudi A.; Nock B.A.; Lymperis E.; Valkema R.; Krenning E.P.; de Jong M.; Maina T.; Impact of clinically tested NEP\/ACE inhibitors on tumor uptake of [111In-DOTA]MG11-first estimates for clinical translation. EJNMMI Res 2016,6(1),15","journal-title":"EJNMMI Res"},{"key":"ref=102","doi-asserted-by":"publisher","first-page":"8957","DOI":"10.1002\/anie.201303108","volume":"52","author":"Valverde I.E.","year":"2013","unstructured":"Valverde I.E.; Bauman A.; Kluba C.A.; Vomstein S.; Walter M.A.; Mindt T.L.; 1,2,3-Triazoles as amide bond mimics: triazole scan yields protease-resistant peptidomimetics for tumor targeting. Angew Chem Int Ed Engl 2013,52(34),8957-8960","journal-title":"Angew Chem Int Ed Engl"},{"key":"ref=103","doi-asserted-by":"publisher","first-page":"57","DOI":"10.1016\/j.nucmedbio.2017.06.001","volume":"52","author":"Maina T.","year":"2017","unstructured":"Maina T.; Kaloudi A.; Valverde I.E.; Mindt T.L.; Nock B.A.; Amide-to-triazole switch vs. in vivo NEP-inhibition approaches to promote radiopeptide targeting of GRPR-positive tumors. Nucl Med Biol 2017,52,57-62","journal-title":"Nucl Med Biol"},{"key":"ref=104","doi-asserted-by":"publisher","first-page":"S20","DOI":"10.1016\/S0969-8051(19)30243-4","volume":"72-73","author":"Grob N.","year":"2019","unstructured":"Grob N.; B\u00e9h\u00e9 M.; Schibli R.; Mindt T.P.C.; #50 -177Lu-labelled peptidomimetics: novel minigastrin analogues for improved tumour targeting. Nucl Med Biol 2019,72-73,S20","journal-title":"Nucl Med Biol"},{"key":"ref=105","doi-asserted-by":"publisher","first-page":"166","DOI":"10.1021\/jm00053a022","volume":"36","author":"Corringer P.J.","year":"1993","unstructured":"Corringer P.J.; Weng J.H.; Ducos B.; Durieux C.; Boudeau P.; Bohme A.; Roques B.P.; CCK-B agonist or antagonist activities of structurally hindered and peptidase-resistant Boc-CCK4 derivatives. J Med Chem 1993,36(1),166-172","journal-title":"J Med Chem"},{"key":"ref=106","doi-asserted-by":"publisher","first-page":"2896","DOI":"10.7150\/thno.24378","volume":"8","author":"Klingler M.","year":"2018","unstructured":"Klingler M.; Decristoforo C.; Rangger C.; Summer D.; Foster J.; Sosabowski J.K.; von Guggenberg E.; Site-specific stabilization of minigastrin analogs against enzymatic degradation for enhanced cholecystokinin-2 receptor targeting. Theranostics 2018,8(11),2896-2908","journal-title":"Theranostics"},{"key":"ref=107","doi-asserted-by":"publisher","first-page":"1010","DOI":"10.2967\/jnumed.118.221283","volume":"60","author":"Klingler M.","year":"2019","unstructured":"Klingler M.; Summer D.; Rangger C.; Haubner R.; Foster J.; Sosabowski J.; Decristoforo C.; Virgolini I.; von Guggenberg E.; DOTA-MGS5, a new cholecystokinin-2 receptor-targeting peptide analog with an optimized targeting profile for theranostic use. J Nucl Med 2019,60(7),1010-1016","journal-title":"J Nucl Med"},{"key":"ref=108","doi-asserted-by":"publisher","DOI":"10.3390\/ph12010013","volume":"12","author":"Klingler M.","year":"2019","unstructured":"Klingler M.; Rangger C.; Summer D.; Kaeopookum P.; Decristoforo C.; von Guggenberg E.; Cholecystokinin-2 receptor targeting with novel C-terminally stabilized HYNIC-minigastrin analogs radiolabeled with technetium-99m. Pharmaceuticals (Basel) 2019,12(1)","journal-title":"Pharmaceuticals (Basel)"},{"key":"ref=109","volume":"S268","author":"von Guggenberg E.","year":"2019","unstructured":"von Guggenberg E.; Klingler M.; Garnuszek P.; Mikolajczak R.; Janota B.; Hubalewska-Dydejczyk A.; Kiec-Klimczak M.; Przybylik-Mazurek E.; Virgolini I.;  Gallium-68 labelled minigastrin analogue for high sensitivity PET imaging of cholecystokinin-2 receptor expressing\ntumours 2019,S268","journal-title":"Gallium-68 labelled minigastrin analogue for high sensitivity PET imaging of cholecystokinin-2 receptor expressing\ntumours"}],"container-title":["Current Medicinal Chemistry"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/eurekaselect.com\/article\/download\/183142","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.eurekaselect.com\/183142\/article","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/eurekaselect.com\/article\/download\/183142","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2021,8,16]],"date-time":"2021-08-16T05:47:34Z","timestamp":1629092854000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.eurekaselect.com\/183142\/article"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2020,12,8]]},"references-count":109,"journal-issue":{"issue":"41","published-print":{"date-parts":[[2020,12,8]]}},"alternative-id":["LiveAll1"],"URL":"https:\/\/doi.org\/10.2174\/0929867327666200625143035","relation":{},"ISSN":["0929-8673"],"issn-type":[{"value":"0929-8673","type":"print"}],"subject":[],"published":{"date-parts":[[2020,12,8]]},"assertion":[{"value":"Peer Reviewed","order":0,"name":"review_status","label":"Review Status","group":{"name":"peer_review_details","label":"Peer Review Details"}},{"value":"Single blind","order":1,"name":"review_process","label":"Review Process","group":{"name":"peer_review_details","label":"Peer Review Details"}},{"value":"Checked with iThenticate","order":0,"name":"screening_status","label":"Screening Status","group":{"name":"plagiarism_screening","label":"Plagiarism Screening"}},{"value":"2019-11-07","order":0,"name":"received","label":"Received","group":{"name":"publication_history","label":"Publication History"}},{"value":"2020-05-01","order":1,"name":"revised","label":"Revised","group":{"name":"publication_history","label":"Publication History"}},{"value":"2020-05-13","order":2,"name":"accepted","label":"Accepted","group":{"name":"publication_history","label":"Publication History"}},{"value":"2020-12-08","order":3,"name":"published","label":"Published","group":{"name":"publication_history","label":"Publication History"}}]}}